Outcomes of Transrectal Ultrasound-Guided Prostate Biopsy by the 12-Core Method at Can Tho University Hospital

Prostate prostate cancer (PCa) is a common disease in men, possessing the second-highest incidence rate and the fifth-highest mortality rate worldwide. Diagnosis of PCa depends on factors such as rectal examination, total serum PSA level, and the result of prostate biopsy. Our study aimed to evaluate the results of rectal prostate biopsies taken through the 12-core method under the direction of ultrasound.

To assess the results of transrectal ultrasound-guided prostate biopsy by the 12-core method.

This cross-sectional research was conducted on 60 patients with prostate tumors who had indications for biopsy from 5/2021 to 5/2022 at the Can Tho University of Medicine and Pharmacy Hospital. Our patients were required to score 2 points on the international prostate syndrome score (IPSS) and quality of life (QoL) index. We used descriptive statistics to present the data. Indications for undergoing prostate biopsy were abnormal digital-rectal examination findings and/or an elevated total prostate-specific antigen (PSA) serum level (greater than 10 ng/mL). The participants received prophylactic intravascular bacsulfo (1000 mg) and oral metronidazole (500 mg) before the procedure, which was continued for about 3 days. A Fleet enema was self-administered the night before the procedure for rectal cleansing.

The average age of the patients was 68.72 years, and the most common reason for hospitalization was dysuria (80%). The average IPSS score was 26.21 ± 4.49, and the average QoL index was 3.38 ± 0.67. The mean serum total PSA was 26.11 ng/mL. The PCa detection rate after the biopsy was 40% (24/60), and Gleason’s score for 45.83% (11/24) of these patients was 8 or above. There were two cases of strong rectal bleeding (3.33%) and one case of strong hematuria (1.67%).

Transrectal ultrasound-guided prostate biopsy is a valuable and feasible procedure for the diagnosis of PCa at our hospital.